Bavarian Nordic's reports revenue growth but books deficit

The Danish vaccine maker has published its half-year results on Wednesday, revealing that both the company’s revenue and deficit have grown.

Photo: Sven Hoppe/AP/Ritzau Scanpix

A lot has happened for Bavarian Nordic since last it took stock of its financial performance in a quarterly report.

Revenue from the Danish company’s smallpox/monkeypox vaccine, known regionally as Imvanex/Jynneos/Imvamune, has enabled Bavarian to upgrade its full-year guidance a staggering six times this year. Even so, the guidance, which is maintained for the full year, is less interesting than other financial items this time around.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs